Infant Formula Safety Modernization Act of 2026
Rep. DeLauro Introduces the Infant Formula Safety Modernization Act to Require Stricter Germ Testing
This bill is currently in the early stages of the legislative process and is being reviewed by the House Committee on Energy and Commerce. It was recently introduced and is actively moving forward as it waits for committee action. There are no upcoming votes scheduled at this time.
Legislative Progress
Key Points
- The bill requires infant formula manufacturers to test both their factories and finished products for dangerous germs like botulism. The FDA must create and maintain a list of pathogens that all manufacturers must screen for.
From policy text
“require the Commissioner of Food and Drugs to develop a list of pathogens and microorganisms that infant formula manufacturers must test for in infant formula manufacturing facilities and finished infant formula products, which list shall include clostridium botulinum and such other pathogens and microorganisms as the Secretary designates”
View in full text - If a manufacturer finds a dangerous germ in finished formula, they must notify the government within one business day, even if the product has not been shipped to stores. This ensures early detection of contamination risks.
From policy text
“require the manufacturer of an infant formula to submit to the Secretary a written notification of any positive test result for a pathogen or microorganism referred to in clause (i) in infant formula, not later than one business day following the date of the result, even if the formula has not left the control of the manufacturer”
View in full text - The bill mandates environmental testing in specific zones of manufacturing facilities, including areas adjacent to where formula is made and areas further away but still in the processing environment.
From policy text
“specify the recommended frequency of environmental testing, including requirements for testing in Zones 2 and 3 of an infant formula manufacturing facility”
View in full text - Congress must be notified within one business day whenever the FDA learns about a positive pathogen test in finished formula or issues an enforcement action after a factory inspection. This keeps lawmakers in the loop to respond quickly to potential shortages or safety crises.
From policy text
“the Secretary shall, not later than one business day following the date of such receipt, provide a written notice of such receipt to the appropriate committees of Congress”
View in full text - The new safety standards apply equally to all infant formula sold in the U.S., whether made domestically or imported. The FDA must enforce consistent inspection and compliance standards regardless of country of origin.
From policy text
“require Commissioner of Food and Drugs to establish and enforce clear, consistent inspection and compliance standards for all infant formula products, regardless of their country of origin”
View in full text
Impact Analysis
Personal Impact
Milestones
Referred to the House Committee on Energy and Commerce.
Introduced in House
Related News
4 articles
Bill would hold infant formula manufacturers responsible for contaminated products
Rep. Rosa DeLauro introduced the Infant Formula Safety Modernization Act following a botulism outbreak. The bill requires companies to notify the FDA of positive pathogen tests within 24 hours and mandates expanded testing for dangerous germs like Clostridium botulinum in production facilities.
Formula safety bill would modernize oversight of the infant formula supply
The Infant Formula Safety Modernization Act aims to close gaps in federal oversight. It mandates standardized environmental monitoring inside factories to detect contamination before it reaches products and requires manufacturers to alert the government immediately if dangerous germs are found.
Congressional Bill Would Direct FDA to Enforce Stronger Infant Formula Safety Oversight
This legislative proposal would expand required pathogen testing to include a comprehensive list of microorganisms. It compels manufacturers to notify the FDA of any positive test result even if the formula has not left the facility, ensuring earlier intervention in potential safety crises.
Source Information
Document Type
Congressional Bill
Official Title
Infant Formula Safety Modernization Act of 2026
Data Sources
Sponsor
Cosponsors
(18)Analysis generated by AI. Always verify with official sources.